XML 112 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions Preliminary Purchase Price Allocation (Details) - USD ($)
$ in Millions
3 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Sep. 27, 2023
Sep. 26, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]            
Goodwill $ 6,219.2 $ 6,219.2     $ 5,749.0 $ 5,761.1
Reata Pharmaceuticals, Inc            
Business Acquisition [Line Items]            
Cash and cash equivalents 267.3 267.3   $ 267.3    
Accounts receivable 15.9 15.9   15.9    
Inventory 1,259.0 1,259.0 $ 1,300.0 1,692.0    
Measurement Period Adjustments, Inventory (433.0) 31.5        
Other current assets 53.6 53.6   53.6    
Operating lease assets 121.2 121.2 121.2 122.4    
Measurement Period Adjustments, Operating lease assets (1.2)          
Accrued expense and other (101.5) (101.5)   (98.9)    
Measurement Period Adjustments, Accrued expense and other (2.6)          
Debt payable (159.9) (159.9)   (159.9)    
Contingent payable to blackstone (300.0) (300.0)   (300.0)    
Deferred tax liability (912.4) (912.4)   (922.5)    
Measurement Period Adjustments, Deferred tax liability 10.1          
Operating lease liabilities (151.8) (151.8) (151.8) (151.8)    
Other assets and liabilities, net (2.5) (2.5)   (2.0)    
Measurement Period Adjustments, Other assets and liabilities, net (0.5)          
Total identifiable net assets 6,728.9 6,728.9   6,136.1    
Measurement Period Adjustments, Total identifiable net assets 592.8          
Goodwill 464.5 464.5 464.5 1,057.3    
Measurement Period Adjustments, Goodwill (592.8)          
Total assets acquired and liabilities assumed 7,193.4 7,193.4   7,193.4    
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)            
Business Acquisition [Line Items]            
Intangible assets: 4,200.0 4,200.0 4,200.0 3,600.0    
Measurement Period Adjustments, Intangible assets: 600.0          
Reata Pharmaceuticals, Inc | In-process research and development            
Business Acquisition [Line Items]            
Intangible assets: 2,300.0 2,300.0 2,300.0 1,900.0    
Measurement Period Adjustments, Intangible assets: 400.0          
Reata Pharmaceuticals, Inc | Priority review voucher            
Business Acquisition [Line Items]            
Intangible assets: 100.0 100.0   100.0    
Reata Pharmaceuticals, Inc | Other clinical programs            
Business Acquisition [Line Items]            
Intangible assets: 40.0 $ 40.0 $ 40.0 $ 20.0    
Measurement Period Adjustments, Intangible assets: $ 20.0